20 articles
A Phase 2 trial investigates whether thiethylperazine, a decades-old antiemetic, can flush toxic amyloid beta from the brains of early AD patients.
Contraloid acetate, an oral all-D-peptide designed to disassemble toxic amyloid-beta oligomers, completed its first-in-human safety trial in 40 healthy volunteers.
A Phase 1/2 trial tests whether dexmedetomidine can enhance the brain's glymphatic system to clear amyloid and tau during sleep.
A first-in-human multiple-ascending-dose trial tests Contraloid, an oral peptide designed to disassemble toxic amyloid-beta oligomers linked to Alzheimer's disease.
Italian researchers developed a biosensor to track extracellular vesicles in blood, potentially personalizing stroke rehabilitation.
A completed Mount Sinai RCT tested whether HBOT can improve brain blood flow and cognition in diabetic elders with mild cognitive impairment.
TONTT2 tests whether erythropoietin dose and timing can be optimized to best preserve vision after traumatic optic neuropathy.
A VA-sponsored trial tested whether the blood pressure drug prazosin could remove toxic proteins linked to CTE and Alzheimer's in combat veterans.
Personalized treatment approach targeting multiple causes of cognitive decline outperformed standard care in 9-month trial.
A completed Phase 1/2 pilot trial tested whether the senolytic duo D+Q penetrates the brain in early Alzheimer's disease.
Pilot study tests psilocybin-assisted psychotherapy to help hospice patients overcome demoralization and existential suffering.
A completed pilot trial tests adapted Dialectical Behavior Therapy to reduce suicidality in aging family caregivers of AD/ADRD patients.
A Phase 4 RCT tests whether one bevacizumab injection matches two combined doses for neovascular AMD outcomes over 12 months.
A Phase 2 open-label trial explores whether an approved immune drug can raise frataxin protein levels and slow neurological decline in Friedreich Ataxia.
Study tested whether pimavanserin could prevent return of hallucinations and delusions in dementia patients who initially responded to treatment.
Novel movement program combining Eastern and Western exercises may help maintain independence and cognitive function in dementia patients.
Probucol, a discontinued cholesterol medication, may boost brain-protective proteins in older adults at risk for dementia.
Researchers at Duke University tested a blood-based biomarker to stratify Alzheimer's patients from healthy adults, aiming to enable earlier detection.
French pilot study tests psychedelic therapy for patients with alcohol use disorder and comorbid depression after withdrawal.
Small study tests psychedelic compound's safety and effectiveness against severe depression that doesn't respond to standard treatments.
